CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction Criteria for Iron Deficiency in Patients With Heart Failure Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction

Clinical Trial2018 Jun 12;71(23):2628-2639.

JOURNAL:J Am Coll Cardiol. Article Link

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Kosiborod M, Lam CSP, CVD-REAL Investigators and Study Group. Keywords: SGLT-2 inhibitor; death; diabetes mellitus; heart failure; observational studies; sodium glucose cotransporter-2 inhibitors

FULL TEXT PDF